良性前列腺增生并发前列腺炎患者前列腺液白细胞介素水平与前列腺特异性抗原的相关性研究

目的研究良性前列腺增生(BPH)并发前列腺炎患者的前列腺液白细胞介素水平和前列腺特异性抗原(PSA)的相关性。方法回顾本院2014年7月到2018年1月本院收治的115例良性前列腺增生患者的临床资料,分析其并发前列腺炎的情况、前列腺液白细胞介素水平、总PSA(TPSA)和游离PSA(FPSA)及FPSA/TPSA。结果115例BPH患者中有76例并发前列腺炎,其中I级炎症37例、II级炎症25例、III级炎症13例。III级炎症组的炎症范围、炎症程度均显著高于I级、II级炎症组,差异均有统计学意义(P<0.05)。III级炎症组的IL-2、IL-6、IL-8、IL-10均显著高于I级炎症组、II级炎症组,差异均有统计学意义(P<0.01)。III级炎症组的TPSA、FPSA显著高于I级炎症组、II级炎症组,差异均有统计学意义(P<0.01);三组的FPSA/TPSA比较,差异无统计学意义(P>0.05)。经Pearson直线相关法分析,BPH并发前列腺炎患者的前列腺液IL-2与PSA、FPSA均无显著相关性(P>0.05);前列腺液IL-6、IL-8、IL-10与TPSA、FPSA均呈显著正相关(P<0.05)。结论BPH并发前列腺炎是患者PSA升高的危险因素,且患者前列腺液的IL-6、IL-8、IL-10水平与PSA存在良好的相关性,临床可据此进行BPH并发前列腺炎的诊断和治疗,以提高临床疗效。     

Specific red cell adherence test in benign and malignant lesions of the prostate

The specific red cell adherence test (SRCA) for blood group antigens has been shown to have some bearing on the invasive potential of bladder tumours. Hitherto there have been few data published from patients with prostatic disease. The results of SRCA testing in 69 such patients are presented. Each of the 30 cases of adenocarcinoma was antigen negative. However, as 18 of 39 patients with only benign hyperplasia were also antigen negative, the test clearly does not reflect extant tumour and is probably not an indicator of subsequent growth of prostatic cancer. Antigen expression was also negative in sections showing prostatitis. As the test was invariably negative in patients with adenocarcinoma, whether or not metastases were present and whatever the degree of differentiation of the primary tumour, it lacks the power to discriminate invasive potential.     

前列腺癌患者的红细胞免疫功能及T淋巴细胞亚群变化观察

目的探讨前列腺癌患者红细胞免疫功能状态及与Ｔ淋巴细胞亚群改变的关系。方法测定１２例前列腺癌患者的红细胞Ｃ３ｂ受体花环率（Ｃ３ｂＲＲ）、免疫复合花环率（ＩＣＲ）及四项肿瘤红细胞花环率（ＤＴＥＲ、ＥＴＥＲ、ＡＴＥＲ、ＮＴＥＲ）,用流式细胞仪（ＦＣＭ）检测Ｔ细胞亚群,与年龄相近的１５例良性前列腺增生症（ＢＰＨ）患者作比较,并测定了２０名健康献血员的红细胞免疫指标作对照。结果前列腺癌组Ｃ３ｂＲＲ降低,ＣＤ３、ＣＤ４及ＣＤ４／ＣＤ８均低于ＢＰＨ组。ＢＰＨ组Ｃ３ｂＲＲ和ＤＴＥＲ低于对照组。前列腺癌组Ｃ３ｂＲＲ与ＣＤ４／ＣＤ８比值呈正相关。结论前列腺癌患者红细胞免疫功能低下,Ｔ淋巴细胞免疫活性下降,两者关系密切。前列腺癌易发生血行扩散可能与红细胞免疫功能低下有关。ＢＰＨ患者红细胞免疫粘附能力降低为老年性改变。     

Prostate tumour markers and differentiation grade in prostatic cancer.

Serum acid phosphatase activity, prostate specific phosphatase and prostate specific antigen were measured in 100 patients with prostatic cancer. The patients were divided according to the differentiation grade into 3 groups: G1 (well), G2 (moderately) and G3 (poorly differentiated) carcinoma. Bone metastases were identified by scintigraphy. Among the 76 M0 patients the mean levels of all 3 markers were slightly higher in patients with moderately differentiated prostatic carcinoma. Among the 24 M1 patients the primary tumour was either G2 (18 patients) or G3 (6 patients); none had G1 lesions. Significantly higher serum ACP and PAP levels were found in patients with G2 tumours than in those with G3 lesions. It was concluded that the histological differentiation grade of prostatic carcinoma did affect serum levels of prostatic tumour markers; the tendency towards higher levels in the G2 group was noticeable in both non-metastatic and metastatic cases despite the limited number of patients in the latter category. In clinical practice this information may be an important additional tool in staging prostatic cancer.     

Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276

A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.     

Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate

We examined the relationship between age and pathological stage in 444 consecutive patients who underwent pelvic lymphadenectomy and radical retropubic prostatectomy for clinically localized adenocarcinoma of the prostate. Pathological stage of cancer was determined postoperatively as organ-confined, capsular penetration (cancer through prostatic capsule), seminal vesicle involvement or lymph node metastases. Patient age ranged from 34 to 75 years. The majority of the patients had clinical stage B1 disease with induration confined to less than 1 lobe of the gland. In this group a statistically significant (p equals 0.001, chi-square test for trend) correlation between increased age and higher pathological stage was found. We also found that older men with clinical stage B1 disease had a statistically significant trend toward higher Gleason grade. An explanation for our findings might be the masking of prostatic induration by benign prostatic hypertrophy, clearly a disease of aging men. We suggest that increased age is a relative risk factor for advanced pathological findings in men with clinical stage B1 prostatic cancer.     

Transabdominal ultrasonography in the evaluation of patients with advanced prostatic carcinoma: effects of castration and of chronic administration of a gonadotropin releasing hormone agonistic analogue

Twenty-two patients with advanced prostatic carcinoma were subjected either to orchiectomy (group I, n = 5) or to chronic administration of a gonadotropin releasing hormone agonistic analogue D, Ser (TBU)6, des Gly-NH2(10) LHRH nonapeptide (HOE 766) (group 2, n = 17). Plasma testosterone was similar in both groups prior to treatment (group 1: 636 +/- 129.29, group 2: 580.85 +/- 37.57; X +/- SE). The levels attained in group I were significantly lower (P less than .05) than those of group 2 through eight weeks of follow-up but were similar by the third month. Prostatic size (cm2) as estimated by transabdominal ultrasonography did not differ between the two groups prior to treatment (group 1: 23.6 +/- 3.35, group 2: 21.4 +/- 1.97; X +/- SE). Both therapies resulted in a decrease of prostatic size that was significantly more pronounced (P less than .05) in group I compared with group 2 by the first and third month; by the six month, there was no statistical difference in the prostatic size attained with either therapeutic modality. Persistent suppression of prostatic size was documented in all patients of group 2 chronically (up to 24 months) treated with HOE 766 even when there was evidence of uninhibited or progressive bony metastases. The above data 1) indicate the efficacy of the HOE 766 in inducing medical castration and prostatic shrinkage in advanced carcinoma of the prostate, 2) document the usefulness of transabdominal ultrasound in the follow-up of such patients, and 3) suggest a relationship between the rapidity of tumor shrinkage and Leydig cell suppression.     

解毒定痛方预防骨转移瘤放疗爆发痛的临床疗效观察

目的:探析解毒定痛方预防骨转移瘤放疗爆发痛的临床治疗效果。方法:选取2019年8月—2020年9月河北省沧州中西医结合医院收治的恶性肿瘤骨转移患者120例,按照随机数字表法分成实验组与对照组。对照组接受常规药物治疗,实验组在此基础上服用解毒定痛方,对比两组患者治疗前、治疗1周、治疗2周、治疗3周、治疗4周、治疗后1周、治疗后2周、治疗后1月的生活质量(QOL-C30)量表评分、疼痛评分、超敏C反应蛋白(hs-CRP)和白介素-8(IL-8)水平及不良反应的情况。结果:治疗前,两组患者CRP、IL-8、疼痛评分和QOL-C30评分对比无差异(P_均0.05);治疗1周～治疗后2周,两组患者的CRP水平呈逐步降低趋势,且组间对比差异有统计学意义(P_均0.05);治疗2周～治疗后2周,两组患者的CRP、IL-8、疼痛评分和QOL-C30各项评分呈逐步改善趋势,且组间对比有统计学意义(P_均0.05);治疗后1月,两组患者的CRP、IL-8、疼痛评分和QOL-C30各项评分呈逐步改善趋势,且优于治疗前、治疗1周、治疗2周、治疗3周和治疗4周,组间对比有统计学意义(P_均0.05)。实验组疼痛缓解有效率96.67%,中医症状治疗有效率为90.0%,均优于对照组的78.33%和73.33%(P_均0.05)。结论:解毒定痛方能有效减低骨转移瘤患者的CRP和IL-8的水平,改善患者放疗爆发痛的疗效,提升患者生活质量,具有一定的临床应用价值。     

Prostate tumour markers as an aid in the staging of prostatic cancer.

Serum acid phosphatase activity (ACP), prostate specific phosphatase (PAP) and prostate specific antigen (PSA) were measured in 100 patients with prostatic cancer. The patients were divided into 4 groups: T1-2 MO, T3-4 MO and M1 patients with less than or equal to 10 or greater than 10 metastatic foci in bone scintigraphy. The mean serum ACP levels were almost identical in the T1-2 MO and T3-4 MO groups and there was no significant difference between the mean PAP values. Significantly higher PSA levels were observed in the MO patients in the extracapsular category compared with those in the intracapsular category. The mean serum levels of all 3 tumour markers were significantly higher in the M1 than in the MO category. PSA seems to be the marker of choice as a diagnostic aid for differentiating between patients with intracapsular and those with extracapsular tumour growth. In prostatic cancer patients with bone metastases these markers were of similar value for staging the disease.     

Deoxythymidine kinase in the staging of prostatic adenocarcinoma

The role of prostate-specific antigen in the management of prostatic adenocarcinoma is still not fully ascertained. Its place in the monitoring of patients who have undergone radical treatment is without question but its role in the primary assessment of a lesion is a point of continuous discussion. This study reports the analysis of prostate-specific antigen (PSA) in 92 patients with different stages of prostatic adenocarcinoma prior to treatment; in the case of the localized lesions, this was based to a great extent on the findings at lymphadenectomy. Apart from PSA analysis, deoxythymidine kinase (dTK) analyses were also performed in an attempt to discover whether the latter could provide additional information about the tumor load in the different patient categories, viz. those with lymph node involvement (group 1), those with lymph node involvement but without distant metastases (group 2), and those with disseminated disease (group 3). The median PSA and dTK values in groups 1–3 were 6.5 μg/L and 2.7 U/μl, 16 μg/L and 2.6 U/μL, and 90 μg/L and 7.8 U/μL, respectively. If the two analyses were used concomitantly, they could differentiate true localized disease from metastatic in approximately 92% of cases. The combination should prove of value in the primary assessment of a patient with a newly diagnosed prostatic adenocarcinoma. © 1996 Wiley-Liss, Inc.     

Total bone uptake in management of metastatic carcinoma of the prostate

The status of patients with skeletal metastases from prostatic carcinoma was determined from a quantitative uptake and retention measurement of the bone scanning radiopharmaceutical 99mtechnetium-methylene diphosphonate. Whole body counts were performed 5 minutes and 24 hours after intravenous administration of 99mtechnetium-methylene diphosphonate, and were expressed as the percentage uptake by the skeleton at 24 hours. Skeletal uptake determinations were done in 29 patients with prostatic cancer (17 with osseous metastases) who were evaluated at 3 to 6-month intervals. Group 1 consisted of patients who responded to therapy and achieved remission, group 2 included patients with relapse or progressive disease, group 3 consisted of those with metastases who were in remission for longer than 6 months and group 4 included those without evidence of any bony metastases. The baseline mean +/- standard deviation 24-hour skeletal uptake values were 46.1 +/- 12.0 per cent in group 1, 34.3 +/- 13.9 per cent in group 2, 27.0 +/- 5.9 per cent in group 3 and 28.9 +/- 5.5 per cent in group 4. At 3 to 6 months the values in group 1 (responders) decreased by 18 per cent, while those in group 2 (relapse or progression) increased by 19 per cent and those in group 3 (remission) increased by 1.5 per cent. The quantitative 24-hour skeletal uptake test was performed easily, reproducible and at least as useful as concurrent chemical blood tests and subjective bone scan interpretations.     

Squamous metastases from prostatic adenocarcinoma

Two patients with prostatic adenocarcinoma are reported whose metastases harbored large foci of squamous cell carcinoma. The prostatic origin of such areas was proven by immunoperoxidase staining for prostatic acid phosphatase (PAP) as well as the identification of transition zones between adenocarcinoma and squamous cell carcinoma. The possible role of estrogen therapy in inducing the squamous change is discussed.     

Significance of the concentrated red cell and albumin priming method with particular reference to anaphylatoxin generation.

Anaphylatoxins generated by cardiopulmonary bypass were observed in basic and clinical studies (n = 120 in the latter). In vitro immunoglobulin fractions denatured by oxygen bubbling produced C4a, C3a, and C5a, but albumin identically treated did not. Therefore concentrated red cells with albumin were used to prime homologous blood for clinical application during cardiopulmonary bypass. Complement levels were compared with type of oxygenator (bubble or membrane) and the ratio of primed homologous blood to circulating autologous blood volume. With the bubble oxygenator at a low ratio of homologous to autologous blood (arbitrarily defined as less than 20%), C3a levels during cardiopulmonary bypass tended to be lower in the concentrated red cells plus albumin priming group than in the ordinary priming group (p less than 0.1, at 60 and 90 minutes of cardiopulmonary bypass). C4a and C3a levels increased less after protamine administration with concentrated red cells plus albumin priming (p less than 0.05, p less than 0.01, respectively, 90 minutes after protamine) than with ordinary priming. Such changes in the membrane oxygenator group were less remarkable. Thus C3a levels were approximately the same in both oxygenator groups primed with concentrated red cells plus albumin. The higher the homologous to autologous ratio, the steeper the C4a and C3a increase from the beginning of cardiopulmonary bypass with the bubble oxygenator. This tendency was less remarkable in the membrane oxygenator group. Early postoperative pulmonary function was improved by concentrated red cells plus albumin priming, especially in the bubble oxygenator group. In conclusion, (1) oxygenator systems primed with concentrated red cells plus albumin produced less anaphylatoxin than those with homologous blood, especially with the bubble oxygenator, and (2) our clinical results support the importance of immunoglobulin denatured by oxygen bubbling in anaphylatoxin generation (by means of the classical pathway), as shown by our in vitro study.     

Comparison of Hormonal Therapy and Chemohormonal Therapy in Patients with Newly Diagnosed Clinical Stage D Prostatic Cancer

Background: In order to examine the usefulness of chemohormonal therapy, we conducted a multicentered randomized trial comparing hormonal therapy, using a luteinizing hormone-releasing hormone (LH-RH) agonist, with chemohormonal therapy, hormonal therapy plus cyclophosphamide (CPM), in patients with newly diagnosed clinical stage D prostatic cancer.
Methods: Between January 1991 and March 1995, 41 evaluable patients with stage D prostatic cancer were randomized into 2 groups: group A (hormonal therapy alone), goserelin acetate depot 3.6mg subcutaneously every 4 weeks; group B (chemohormonal therapy), goserelin acetate depot 3.6mg subcutaneously and CPM 1000mg/m² intravenously every 4 weeks. The responses to the therapies were evaluated based on the criteria of The Japanese Urological Association.
Results: There were no significant differences between the 2 groups with regard to objective and subjective response rates. No advantage in chemohormonal therapy was observed in the survival rate and progression-free survival rate. However, the survival rate and progression-free survival rate of responders were significantly higher than those of nonresponders in both groups. When the results were categorized by histologic grade patients with poorly-differentiated adenocarcinoma had significantly higher response rates, survival rates, and disease-progression-free survival rates in Group B compared to similar patients in Group A.
Conclusions: We conclude that chemohormonal therapy does not definitely improve the clinical response and prognosis of patients with stage D prostatic cancer; however, for patients with poorly-ditferentiated adenocarcinoma, chemohormonal therapy is a useful treatment.     

经尿道前列腺电切术与1470 nm半导体激光汽化术治疗前列腺增生的疗效比较

【摘要】 目的 对经尿道前列腺电切术和1470 nm半导体激光汽化术治疗前列腺增生的临床疗效的比较。方法〓收集2014~2015年采用不同方法治疗前列腺增生患者的临床资料,选择1470 nm半导体激光汽化术治疗和TURP治疗的BPH患者各50例,分治疗组和对照组,2组术前临床参数比较无统计学意义(P>0.05)。对两组手术情况、随访情况及并发症发生率进行比较。结果〓采用1470 nm半导体激光汽化术治疗组显示良好临床效果,两组在手术时间、术中出血量、术后留置导尿管时间和术后住院时间的差异均有统计学学意义(P<0.05)。术后3个月随访,2组IPSS、Qmax、RUV与术前相比及组间术后相比差异均有显著性意义(P<0.05);治疗组与对照组并发症发生率分别为6%和26%,差异有统计学意义(P<0.05)。结论〓TUPR和1470 nm半导体激光汽化术均能有效的治疗前列腺增生,但1470 nm半导体激光汽化术术中出血量少,导尿管留置时间短,并发症少,安全性高,效果更好。     

Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer

BACKGROUND: We present our initial experience with the use of the squamous cell carcinoma (SCC) antigen (SCCAg) in 16 men with penile SCC (SCC group), in four men with condyloma acuminatum (benign group), and in 32 blood donors (control group). METHODS: The SCCAg levels were measured at presentation and every 6 months (upper limit was 2 ng/mL). The mean follow-up time was 4 years. RESULTS: All non-SCC patients had normal SSCAg serum levels in contrast with the SCC patients. The presence of nodal and/or distant metastases resulted in statistically significant higher SCCAg levels, both at presentation and during the follow-up. In patients undergoing lymph node dissection with elevated SCCAg levels prior to the procedure, there was a statistically significant decrease of the SCCAg levels after the operation. CONCLUSION: The SCCAg level could be a serum marker that holds promise for clinical use in penile SCC. Sequential monitoring of SCCAg level might indicate developing of nodal and/or distant metastases and could be useful in following the response to treatment.     

New cut-off point between T1 and T2 renal cell carcinoma - necessary for a better discriminatory power of the TNM classification

PURPOSE: We evaluated the pathological features of tumor size, lymph node and distant metastases, cell type, growth pattern, infiltration pattern, histological grade, local invasion and venous involvement of organ-confined renal carcinomas. The aim of this study was the re-evaluation of the TNM classification and the tumor cut-off point between T1 and T2 for renal cell carcinomas from the 1987 to the 1997 versions. MATERIALS AND METHODS: (1) Patients with renal cell carcinoma who had been operated between October 1992 and August 2001 were evaluated. 437 of 691 patients showed T1 and T2 tumors. These organ-confined tumors have been divided into five groups: group 1: tumor-size of 20 mm or less (n = 16), group 2: 21-30 mm (n = 79); group 3: 31-40 mm (n = 83; group 4: 41-70 mm (n = 184), and group 5: more than 70 mm in diameter (only T2, n = 75). Follow-up ranged from 0 to 100 months (average 28.63 months). (2) Of 15,347 autopsies performed in Jena between 1985 and 1996, 272 renal cell carcinomas were revealed. In 145 of these 272 cases renal cell carcinomas were limited to the kidney. These 145 tumors were divided accordingly into 5 groups: group 1: 20 mm or less (n = 33), group 2: 21- 30 mm (n = 31); group 3: 31-40 mm (n = 29); group 4: 41-70 mm (n = 42), and group 5: T2 (n = 10). Clinicopathological criteria examined were lymph node and distant metastases, cell type, growth pattern, infiltration pattern, histological grade, local invasion and venous involvement. To identify the optimal cut-off point between T1 and T2 disease the chi2 test was used. RESULTS: (1) In the clinical series only 1.8% (n = 8) of all cases showed lymph node metastases. Distant metastases were shown in 57 cases (13.04%); within group 1: 0%, group 2: 7.59%, group 3: 1.20%, group 4: 15.76%, group 5: 28%. The tumor grading was statistically correlated with tumor size. (2) In the pathological series 94 of the evaluated 145 patients were downstaged from T2(1987) to T1(1997). Lymph node and distant metastases were well correlated with tumor size. Lymph node metastases were seen in 0, 12.9, 31, 29.3 and 40% (group 1 to group 5) and distant metastases in 12.1, 25.8, 41.4, 47.7 and 60%. There were no statistically significant differences between T2(1997) and T1(3-7 cm). The tumor grading was statistically correlated with tumor size (grade 1: in 66.7, 25.8, 17.2, 9.5 and 0%). CONCLUSION: Our data suggest that the current cut-off diameter between T1 and T2 renal cell carcinomas (7 cm) is too high. Lowering the cut-off level will result in better discriminatory power of the TNM classification. From our data, we conclude that the cut-off diameter should be lowered to 3.5 cm (p < 0.001).     

Results of surgical treatment in bronchioloalveolar carcinoma

The study relates to patients with bronchioloalveolar carcinoma who had undergone operation. On reassessment of histological specimens, 92 patients were considered to have been suffering from bronchioloalveolar carcinoma. Bronchioloalveolar carcinoma was further classified according to histological findings as typical or of mixed type. The latter included cases on which there was differentiation towards pulmonary adenocarcinoma. A third group consisted of 32 cases of peripheral pulmonary adenocarcinoma originally diagnosed as bronchioloalveolar carcinoma. Pulmonary tuberculosis was found to have occurred oftener in bronchioloalveolar carcinoma cases than in mixed bronchioloalveolar cases (p less than 0.005). A history of pneumonia was commoner in mixed bronchioloalveolar and adenocarcinoma patients than in bronchioloalveolar patients (p less than 0.05). Lobectomy or more conservative resection had been possible in the majority of cases. There had been no surgical or hospital mortality. No differences existed between the groups as regards surgical treatment, postoperative radiotherapy or chemotherapy. Local recurrence was commoner in bronchioloalveolar patients than in mixed bronchioloalveolar patients (p less than 0.001) or adenocarcinoma patients (p less than 0.025). Mixed bronchioloalveolar and adenocarcinoma patients had distant metastases oftener than bronchioloalveolar patients (p less than 0.025 and p less than 0.001). Adenocarcinoma patients also had more metastases than mixed bronchioloalveolar patients, but the difference was not statistically significant. Most metastases (82%) were discovered within three years of operation. The incidence of local recurrences increased from three years after operation. The five-year survival rate was 57% in the bronchioloalveolar group, 45% in the mixed bronchioloalveolar group and 17% in the adenocarcinoma group.(ABSTRACT TRUNCATED AT 250 WORDS)     

元贝合剂对前列腺增生患者转化生长因子α及尿流率的影响

目的分析元贝合剂对前列腺增生患者转化生长因子α(TGF-α)及尿流率的影响,评价元贝合剂辅助治疗前列腺增生的疗效,分析其起效机制。方法2017年1月至2018年4月,医院泌尿科收治的前列腺增生患者92例入组,均采用保守治疗,对照组和观察组各46例,按照随机数字表达法分组。两组均给予基础治疗,对照组加用爱普列特,5 mg每次,1日2次,持续4周。观察组联合元贝合剂,1日1剂,持续4周。对比治疗前后临床疗效、尿转化生长因子α及尿流率、国际前列腺症状评分(IPSS)。治疗过程中,观察两组不良反应。结果观察组与对照组组内对比尿转化生长因子α低于治疗前,差异有统计学意义(P<0.05),两组组间对比治疗后,观察组尿转化生长因子α水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组与对照组组内对比尿流率(Qmax、Qave)高于治疗前,组间对比观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组与对照组组内对比IPSS评分低于治疗前,组间对比观察组低于对照组,差异有统计学意义(P<0.05)。观察组整体疗效优于对照组,差异有统计学意义(P<0.05)。结论元贝合剂治疗前列腺增生疗效肯定,可以降低尿转化生长因子α水平,提升尿流率、缓解患者病情。     

Urinary hydroxyproline levels in patients with prostatic carcinoma

In this study daily urinary hydroxyproline (HOP) levels were evaluated in 26 patients with advanced prostatic cancer and 15 patients with BPH. In patients with prostatic cancer — the ones with bone metastases proved by bone scanning — urinary HOP levels were found to be 69.58 mg/l/day and in those without metastases the levels amounted to 22.55 mg/l/day. In patients with BPH, serving as controls, urinary HOP was 12.80 mg/l/day. Urinary HOP levels in cancer patients were statistically higher than in the control group. This difference was even more significant in patients with bone metastases. The method detects small metastatic foci of low activity, therefore it may be used also in smaller centres and for effective monitoring of therapy.